These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32658260)

  • 1. Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation: A Teachable Moment.
    Edward JA; Gopal RK
    JAMA Intern Med; 2020 Sep; 180(9):1246-1247. PubMed ID: 32658260
    [No Abstract]   [Full Text] [Related]  

  • 2. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
    Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Fanikos J
    J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
    [No Abstract]   [Full Text] [Related]  

  • 7. Stroke prevention in atrial fibrillation: Closing the gap.
    Pokorney SD; Gersh BJ; Ahmad A; Al-Khatib SM; Blank M; Coylewright M; DiBattiste P; Healey JS; Hedrich O; Hylek EM; Kline-Rogers E; Peterson ED; Mendys P; Mirro MJ; Naccarelli G; Patel P; Ruff CT; Rutman H; Stockbridge N; Temple R; Granger CB
    Am Heart J; 2019 Apr; 210():29-38. PubMed ID: 30731371
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple antithrombotic therapy with aspirin, a thienopyridine derivative plus oral anticoagulation in patients with atrial fibrillation undergoing coronary stenting.
    Pipilis A; Lazaros G; Tsakonas G; Stefanadis C
    Hellenic J Cardiol; 2010; 51(4):330-7. PubMed ID: 20650831
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmaco-utilization and outcomes in patients treated with oral anticoagulants from 2014 to 2015: evidences from administrative databases of the Romagna Local Health Unit].
    Degli Esposti L; Perrone V; Saragoni S; Buda S; Piovaccari G
    G Ital Cardiol (Rome); 2020 Jan; 21(1):25-33. PubMed ID: 31960832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
    Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
    Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Potpara TS; Lip GY
    JAMA; 2017 Mar; 317(11):1115-1116. PubMed ID: 28208176
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison between vitamin K antagonists and new oral anticoagulants.
    Jolobe OMP
    Br J Clin Pharmacol; 2017 Nov; 83(11):2589-2590. PubMed ID: 28703392
    [No Abstract]   [Full Text] [Related]  

  • 14. Critical appraisal of the AUGUSTUS trial.
    Gremmel T; Sulzgruber P; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):187-188. PubMed ID: 31265054
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological properties and clinical efficacy of apixaban (Eliquis(®)].
    Imai N; Fujii Y; Amano M
    Nihon Yakurigaku Zasshi; 2013 Nov; 142(5):247-54. PubMed ID: 24212595
    [No Abstract]   [Full Text] [Related]  

  • 16. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
    Healey JS; Hart RG; Pogue J; Pfeffer MA; Hohnloser SH; De Caterina R; Flaker G; Yusuf S; Connolly SJ
    Stroke; 2008 May; 39(5):1482-6. PubMed ID: 18323500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
    Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
    Sennesael AL; Dogné JM; Spinewine A
    JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.